Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.…
Spero Therapeutics Announces Third Quarter 2026 Operating Results and Provides Business Update
Spero Therapeutics (NASDAQ: SPRO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 25 employees.
The shares were at 0.7420 USD on 20 November 2026, down 69.0% over 52 weeks. Its 52-week range is 0.7301 USD to 3.080 USD: the price is 75.9% below the high and 1.6% above the low.
Its market capitalisation is 43.23M USD.
Spero Therapeutics reports return on equity of 14.5% and an operating margin of 16.9%.
It holds more cash than debt, a net cash position of 107.93M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 25 March 2027.